Houston-based Proxima Clinical Research has expanded its footprint thanks to a recent partnership. Image via proximacro.com

Houston-based Proxima Clinical Research announced this month that it will expand its clinical trial offerings by adding NEXT Oncology to its Early Phase Oncology Network, or EPON.

NEXT Oncology is a Phase I clinical trial treatment center with locations in Austin, Dallas, San Antonio, and Virginia, as well as international locations in Barcelona and Madrid. These centers provide innovative and investigational treatments and therapies to patients with advanced forms of cancers.

The addition of NEXT Oncology's clinics brings Proxima's oncology network up to 14 physical locations and eight clinical practices, Robbin Frnka, executive director of clinical development and strategy at Proxima CRO tells InnovationMap.

“Early phase oncology trials are some of the most delicate and important trials to conduct, both from a science perspective and in offering hope for late-stage patients,” Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, says in a statement. “We proudly designed NEXT Oncology specifically to bring the best new agents to patients through our specially designed centers located around the world. This new relationship with Proxima CRO’s EPON will help us further enhance our mission and contribute to our life’s work of advancing cancer treatments to save more lives from cancer around the world.”

Proxima is a Houston-based contract research organization focused on supporting life science startups as they grow and scale. It was recently named to the the Inc. 5000 regional rankings for the Southwest for its fast-growing revenue.

The company launched its EPON in March to support Phase I and Phase II clinical oncology trials and a group of oncology-specific scientific experts. The Mary Crowley Cancer Research, a specialized clinical research center in Dallas, was one of the first to join the network.

"Finding the right clinical sites and investigators with the right patients is one of the biggest struggles of early phase clinical trials," Frnka says in a March statement. "Our Early Phase Oncology Network, which we're calling EPON, includes some of the most prominent investigators in early phase trials. Receiving expert feedback, insight, and guidance from this skilled scientific panel is critical to the success of these earliest phase trials."

In addition to work in the cancer field, Proxima also launched its M1 MedTech accelerator last year aimed at helping startups quickly grow their health tech businesses. Its inaugural cohort included startups with new tech and treatments for heart arrhythmias, ultrasounds, bioelectric implants in the body and more.

The company also recently expanded its footprint within the Texas Medical Center Innovation Factory.

InnovationMap spoke with Proxima CEO and Co-founder Kevin Coker on the Houston Innovators Podcast.

A Houston life science expert shares what she thinks Houston needs to work on to continue growing as an health care innovation ecosystem. Photo via Getty Images

Expert: Houston has potential to be a major hub for life sciences — if it addresses these concerns

guest column

Once upon a time in Houston, a promising startup, let’s call it BioMatrix, set out to revolutionize the world of biomaterials. Their groundbreaking product held immense potential, but the company faced the harsh reality of a lack of funding, resources, and talent in their local life sciences sector.

As they watched well-funded competitors in established hubs like Boston and Silicon Valley flourish, the passionate team at BioMatrix persevered, determined to overcome these challenges, and make their mark in the rapidly evolving world of MedTech and life sciences. But would they ultimately move to a richer life science hub?

Over the years, Houston has emerged as a life sciences hub, fueled by the world's largest medical center, Texas Medical Center, and an expanding network of research institutions, startups, and investors. However, despite all its potential, the city still lags other innovation hubs and isn’t included in many of the lists for top life science ecosystems. The challenges are many-fold, but some primary challenges are associated with lack of capital, trouble with talent acquisition, and weak collaboration.

Despite an uptick in venture capital funding, Houston's life sciences sector still trails the likes of Silicon Valley and Boston. Programs like CPRIT help keep companies within Texas, while Houston's unique advantages, such as lower living costs and the TMC's presence, can attract investments, but ultimately, to secure necessary capital, stakeholders must cultivate relationships with investors, government agencies, and other funding sources to infuse more money into the Houston ecosystem. And, when individuals try to do this, the rest of the ecosystem must be supportive.

Talent retention and attraction pose another challenge, as Houston competes with well-funded life science hubs offering abundant research institutions and funding opportunities. While Houston boasts numerous educational institutions producing skilled life sciences graduates, many curricula primarily prepare students for academic rather than industry careers, creating a skills and knowledge gap.

Having a lot of experience in academia doesn’t often translate well into the industry, as is demonstrated by many startup founders who struggle to understand the various stakeholder requirements in bringing a life science product to market.

To bridge this, educational institutions should incorporate more industry-oriented courses and training programs, like Rice University’s GMI Program, that emphasize practical skills and real-world applications. Collaborating with local companies for internships, co-op placements, and hands-on experiences can expose students to industry practices and foster valuable connections.

For any life science company, navigating the intricate regulatory landscape is also a challenge, as missteps can be disastrous. However, it’s even more of a challenge when you lack the fundamentals knowledge of what is required and the skills to effectively engage with industry experts in the space.

To address this, Houston must provide more opportunities for companies to learn about regulatory complexities from experts. Workshops, accelerators, or dedicated graduate and undergraduate courses focusing on regulatory compliance and best practices can facilitate knowledge and experience exchange between regulatory experts and innovators.

The initial inception of M1 MedTech was the result of a personal experience with a company who didn’t understand the fundamentals for regulatory interactions and didn’t know how to appropriately engage with consultants, resulting in time and money wasted.

Enhancing collaboration among Houston's life science stakeholders — including academia, research institutions, healthcare providers, subject matter experts, innovators, and investors — is fundamental for growth. A robust and lively professional network can stimulate innovation and help emerging companies access essential resources.

To this end, Houston should organize more industry-specific events, workshops, and conferences, connecting key life science players and showcasing the city's commitment to innovation. These events can also offer networking opportunities with industry leaders, attracting and retaining top talent. We’ve seen some of this with the Texas Life Science Forum and now with the Ion's events, but we could afford to host a lot more.

Houston's life sciences sector holds immense growth potential, but addressing funding, talent recruitment, regulatory navigation, and collaboration challenges is needed for continued success. By tackling these issues and leveraging its unique strengths, Houston can establish itself as a significant player in the global life sciences arenas. If we wait too long, we won’t be able to truly establish the Third Coast because another player will come into the mix, and we’ll lose companies like BioMatrix to their golden shores.

------

Isabella Schmitt is the director of regulatory affairs at Proxima Clinical Research and principal at M1 MedTech.

Five companies have been selected for a brand new accelerator program in Houston. Image via Getty Images

Houston medtech accelerator announces inaugural cohort

future of health care

A Houston medical technology organization has announced the inaugural cohort of a new early-stage accelerator.

M1 MedTech, launched this year by Houston-based Proxima Clinical Research, announced its Fall 2022 cohort.

“This initial cohort launches M1 MedTech with an interactive 14-week agenda covering the basics every emerging MedTech business needs to progress from a startup to an established solution in their market,” says Sean Bittner, director of programs at M1 MedTech, in a news release.

The accelerator will equip early-stage startups with storytelling, business plan support, investor connections, FDA guidance, research, and more through one-on-one consultations, workships, and in-kind services.

The first cohort includes five startups, per the release from the company:

  1. Linovasc. Providing a long overdue major update to balloon angioplasty devices in over 50 years, the Linovasc solution offers a safer branch occlusion and aortic stent dilatation using a toroidal balloon that expands the aorta uniformly without the ischemia caused by current treatments. The company is founded by Bruce Addis.
  2. Grapheton. Founded by Sam Kassegne and Bao Nguyen, Grapheton's patented carbon materials work with electrically active devices to improve the longevity and outcome of bioelectric implants in the body. Terry Lingren serves as the CEO of the startup.
    • Rhythio Medical. Founded by Kunal Shah and Savannah Esteve, Rhythio is the first preventative approach to heart arrhythmias.The chief medical officer is Dr. Mehdi Razavi.
      • PONS Technology. An AI cognitive functioning ultrasound device attempting to change the way ultrasound is done, PONS is founded by CEO: Soner Haci and CTO: Ilker Hacihaliloglu.
        • Vivifi Medical. Founded by CEO Tushar Sharma, Vivifi is the first suture-less laparoscopic technology that connects vessels to improve male infertility and benign prostatic hyperplasia. The company's senior R&D engineer is Frida Montoya.

          The program includes support from sponsors and experts from: Proxima Clinical Research, Greenlight Guru, Medrio, Galen Data, Merge Medical Device Studio, Venn Negotiation, Engagement PR & Marketing, Aleberry Creative, and others.

          “This is an amazing opportunity for emerging founders to learn the progression of pipelining their ideas through the FDA and absorb the critical strategies for success early in their business development,” says Isabella Schmitt, principal at M1 MedTech and director of regulatory affairs at Proxima CRO, in the release.

          From research and venture capital funding to startup growth and accelerator applications opened, here's what you need to know in Houston innovation news. Photo via Getty Images

          Houston beauty startup raises $1M, medtech accelerator opens apps, and more local innovation news

          short stories

          The month of May has started strong with Houston innovation news, and there might be some headlines you might have missed.

          In this roundup of short stories within Houston startups and tech, local universities share big moves in cybersecurity and plant research, a Houston entrepreneur raises extra seed funding, and more.

          Houston medical technology accelerator opens applications

          This medtech startup accelerator has applications open. Graphic via proximacro.com

          M1 MedTech, Proxima Clinical Research's medical technology accelerator is accepting applications for its fall cohort. The program is seeking five to seven early-stage medical device companies for the three-month program. The cohort companies will have investment opportunities up to $100,000 as a combination of both cash and in-kind services.

          “Our program is unique in that it combines acceleration capital, company building expertise, and the regulatory and clinical services of a top CRO,” says Larry Lawson, a venture partner and investor with M1, in the news release. “Access to the M1 founders’ network, both within and outside of the Texas Medical Center, sets these companies up for success. There’s no better group to build a MedTech company with, period.”

          M1 MedTech, which was announced last year, was created to support early-stage medical device companies with a unique coaching process that will include a curated educational program, interactive workshops where participants can continually build out specific company deliverables, and tailored one-on-one mentoring.

          “Many MedTech companies are launched by innovative first-time founders with strong scientific and medical expertise, but who have never taken a regulated product to market or built a business. After working with so many companies at various stages of this journey to market, both with Proxima CRO and with accelerators from across the country, we realized there was a gap that needed to be filled for these rising founders. They not only need regulatory and clinical assistance from experts with hundreds of success stories in this field, we found they also need assistance with design, manufacturing, business, IP, and so much more,” says Isabella Schmitt, RAC, Director of Regulatory Affairs for Proxima CRO and Principle at M1. “These rising founders need to know what they don’t know; so, we put a lot of thought into what emerging companies and rising executives really need, and from that, we built the M1 curriculum.”

          Applications will remain open until May 31. To apply for the Fall 2022 cohort or to learn more about M1 MedTech, visit m1medtech.com.

          Houston entrepreneur adds $1M to seed round

          Houston-based Upgrade has raised additional seed funding. Photo via LinkedIn

          Houston-based Upgrade Boutique — which uses technology to connect women with high-quality wigs and hair extensions — extended its seed round by $1 million, Fast Company reported. The round's initial seed leaders included Houston-based venture capital firms Artemis Fund and Mercury Fund, as well as Logitech president and CEO Bracken P. Darrell and ANIM.

          “This [investment] will enable us to scale even faster and continue to invest in tools and resources that will improve the consumer experience, and help stylists operate more efficiently,” Winters tells Fast Company. “Based on feedback from the stylists on our platform, we see this as a natural development in the company’s evolution.”

          University of Houston joins cybersecurity initiative

          UH joins group that's advancing cybersecurity. Image via Getty Images

          The University of Houston has joined a consortium that's funded by the U.S. Department of Defense (DoD) to launch a virtual institute that will recruit and train the next cybersecurity generation that will protect entities from cyber warfare, cyber espionage, and attacks on the electromagnetic spectrum.

          The virtual institute is called VICEROY — Virtual Institutes for Cyber and Electromagnetic Spectrum Research and Employ — DECREE and will be led by Northeastern University and offered across five universities, including UH, Northern Arizona University, the University of Texas at Austin, and the University of South Carolina.

          “The VICEROY DECREE virtual institute consortium model is transformational. It brings together the best offerings from multiple institutions to meet the workforce training needs in these domains," says Hanadi Rifai, Moores Professor of civil and environmental engineering and UH team lead on the project, in the news release.

          One major focus for the program is the electromagnetic spectrum, which includes radio waves, and is a critical enabler for communications, navigation, radar, training and other military operations. The DoD has been seeking to hire more than 8,000 cyber workers to help defend the virtual space.

          "We recognize the importance and need for workforce training in cybersecurity, electromagnetism, cryptography and data science. These are areas of specific focus and expertise on our campus,” says Paula Myrick Short, UH senior vice president for academic affairs and provost, in the release.

          The two-year program starts in fall 2022 and is funded by a $1.5 million award from the Griffiss Institute, a nonprofit talent and technology accelerator for DoD and its academic, government, and industry partners around the world.

          Local composting company moves into new Houston space and expands to Austin

          Moonshot has expanded locally and statewide. Photo courtesy of Moonshot

          Houston-based Moonshot Composting has announced its relocation to a 8,225-square-foot space in Northside Village at 1410 Bigelow St. The former Yellow Cab outpost is over five times the size of the originally location.

          Additionally, this month Moonshot will open its doors in the greater Austin area with a facility in Creedmoor, just south of Austin. Moonshot's first commercial customer was Austin-headquartered Tacodeli.

          The company has grown its business to nearly 500 subscribers, including 40 commercials accounts, as well as seven full-time and four part-time employees. Moonshot is diverting 30,000 pounds of food waste a week, with a total of nearly 1,000,000 pounds diverted since July 2020, per a news release.

          “We are excited about our growth and all the individuals and companies getting on board to get food waste out of landfills and onto composting sites,” says Chris Wood, Moonshot principal and co-founder, in the release. “Our new space will make for more efficient operations all around.”

          Moonshot Composting's commercial subscribers include Rice University, Houston Baptist University, The Awty International School, ConocoPhillips, Snooze Eatery, Ostia, and Amli Residential.

          Rice University biologist wins NIH award

          This Rice University scientist has received national recognition for her work plant cell analysis. Photo courtesy of Rice

          A Rice University postdoctoral fellow and molecular and cell biologist has received a prestigious National Institutes of Health award.

          Durre Muhammad of Rice Academy won the MOSAIC (Maximizing Opportunities for Scientific and Academic Independent Careers) K99/R00 award, which is intended to help postdoctoral researchers transition into careers while enhancing diversity within the academic biomedical research workforce, according to a news release from Rice. She's only the fourth individual from Rice to receive this recognition.

          The first two years of the award will support the biologist's work in Bonnie Bartel's lab. She is working on defining the mechanisms by which cells in plants identify and eliminate damaged or obsolete organelles known as peroxisomes, which also play important roles in human aging.

          “Our lab in general works on all things peroxisome, and I mainly focus on the latter stage when it’s ready for degradation,” Muhammad says in the release. “We identify the signals and different mechanisms involved in the process of decay.”

          Muhammad joined Rice in 2018. She earned her Ph.D. in plant and microbial biology at North Carolina State University and her bachelor’s degree in biological sciences from the University of Illinois Chicago. She also has her MBA from Benedictine University. She received an NSF Postdoctoral Fellowship in Biology in 2019.

          “Durre is a fantastic scientist who has brought new perspectives and approaches to my lab,” says Bartel, the Ralph and Dorothy Looney Professor of BioSciences. “We are delighted that NIH has recognized her accomplishments and potential with this award.”

          Proxima Clinical Research has its New Year's resolution and is ready to start working hands on with health tech startups. Graphic via proximacro.com

          Houston organization plans to launch health tech accelerator in 2022

          ready to grow

          A contract research organization based in Houston has announced its new accelerator program aimed at helping startups quickly grow their health tech businesses.

          Proxima Clinical Research released details of M1 MedTech, which expects to launch early next year. The CRO has raised funds to launch and invest in members of the inaugural cohort.

          “Our goal is to move these companies substantially forward in a short amount of time,” says Kevin Coker, CEO of Proxima, in a news release. “Proxima is in a unique position to leverage our experienced team of regulatory, quality, and clinical experts. We won’t be working at arm’s length from these companies. We will be a big part of what they do every day.”

          The program will focus on a small group of companies and the Proxima team will provide hands-on support, including instruction, workshops, and one-on-one mentoring.

          “This will be a unique experience for all parties involved, as Proxima is also a young, yet established, company that is now creating a program to assist companies at an earlier stage,” says Larry Lawson, co-founder of Proxima, in the release. “Our experience in the CRO realm and ability to provide coaching in clinical, regulatory, quality, and go-to-market strategies will only strengthen M1 MedTech’s ability to support the success of emerging companies and provide more life-saving technology to the public.”

          Kevin Coker and Larry Lawson co-founded Proxima in 2017. Photos courtesy

          The accelerator will target Class II and III medical devices for its initial cohort. In the future, Proxima plans to expand to include an even more extensive incubator focused solely on Class III devices, according to the release.

          “M1 will be a place where startups can go to receive concrete resources to further their development. The participant success is our sole focus, and the ultimate goal is to have a substantial impact on the ideation-to-market process for Class II and Class III medical devices,” says Isabella Schmitt, director of regulatory affairs at Proxima and a principal at M1, in the release. “Proxima’s specific expertise alongside our M1 partners will provide resources for all key areas of a medical device entrepreneur’s journey to market and beyond.”

          The M1 MedTech applications will open online in the spring.

          “We don’t view M1 as competitive to other accelerators, rather we believe it will offer a different experience. Our team will strive to create a personalized program where companies have a dedicated touch point throughout the process,” says Sean Bittner, director of programs at M1 MedTech, in the release. “We will also provide specific, tailored connections and resources vetted by our team through professional partnerships, not just a general list of industry contacts.”

          Ad Placement 300x100
          Ad Placement 300x600

          CultureMap Emails are Awesome

          Rice University launches new venture fund for university-affiliated startups

          startup support

          Rice University has launched its new One Giant Leap Ventures Fund I, which will invest in the university’s spinouts and alumni-founded startups.

          The early-stage institutional venture fund will function with a hybrid structure that allows for participation from traditional equity investors and philanthropic investors. According to the university, the fund will invest up to $500,000 per Rice-affiliated company.

          To be considered eligible for funds, companies must use intellectual property licensed by the university or be led or founded by alumni.

          One Giant Leap will draw on support and mentorship from Rice’s pool of 60,000 alumni and aims to create educational opportunities within the investment phases, work with graduate and undergraduate venture students, explore the scaling and commercialization of their ideas, and help investigate all the facets of venture capital.

          “Rice alumni bring an extraordinary depth of experience as entrepreneurs, investors and industry leaders, and One Giant Leap creates new ways to put that expertise to work for the next generation of Rice innovators,” Stephen Bayer, vice president for development and alumni relations, said in a news release. “It strengthens the connection between our alumni and the university while giving them meaningful opportunities to mentor, advise and support Rice-affiliated companies as they grow.”

          The fund held its first close in August and made its first investment into Rice brain health spinout Motif Neurotech. Led by Rice faculty member Jacob Robinson, Motif is working to commercialize a minimally invasive neurostimulator that targets treatment-resistant depression. In May, the FDA approved the company to move forward with its first clinical trial.

          “Research produces breakthrough technologies and our academic environment forms outstanding entrepreneurs,” said Adrian Trömel, the fund’s managing director, a Rice alumnus and a startup founder who also serves as Rice’s interim chief innovation officer.

          One Giant Leap joins the already long list of Rice-led programs that foster innovation, including the Liu Idea Labs for Innovation and Entrepreneurship’s Innovation Fellows and Summer Venture Studio, the Rice Alliance’s Business Plan Competition, the Ion District, Woodside Rice Decarbonization Accelerator, Rice Nexus, the Biotech Launchpad and RBL Ventures and its upcoming 200,000 square-foot research lab the Arc.

          “With One Giant Leap, I am excited that we are creating a unique structure that brings together traditional investment and philanthropic participation to invest in and help catalyze our startups, engage the deep expertise within the Rice ecosystem and transform those strengths into real-world impact,” Trömel added in the release.

          New statewide plan aims to eliminate cervical cancer in Texas by 2032

          fighting cancer

          MD Anderson, on behalf of a coalition of health systems, has announced a new plan to eliminate cervical cancer in Texas.

          The five-year Texas Lone Star Cervical Cancer Elimination Plan was launched during the Cancer Prevention and Research Institute of Texas (CPRIT) 2026 Innovations Conference in Galveston this month.

          The plan focuses on three major pillars with goals to be achieved by 2032:

          • HPV vaccination: Increase the percentage of Texas boys and girls up to date on human papillomavirus (HPV) vaccination by age 15 from 50.5 percent to 80 percent
          • Cervical cancer screening: Raise the share of Texas women up to date on cervical cancer screening from 64 percent to 80 percent
          • Timely follow-up, diagnosis and treatment: Ensure 80 percent of women receive diagnostic follow-up and treatment when needed through community outreach, patient navigation, provider training and survivorship support

          Overall, the coalition wants to see fewer than four new cases of cervical cancer annually per 100,000 Texas women by 2032, according to a news release from MD Anderson. Currently, Texas has an incidence rate of 9.5 women per 100,000 diagnosed with cervical cancer, compared with 7.5 women per 100,000 nationally.

          “Texas has the tools to prevent nearly every case of cervical cancer, but tools can save lives only when people can utilize them,” Dr. Ernest Hawk, vice president and division head of Cancer Prevention and Population Sciences at MD Anderson, said in the release. “The Lone Star Cervical Cancer Elimination Plan gives us a shared roadmap to vaccinate more of our children, screen more of our women and make sure every abnormal result leads to care. With innovations like HPV self-collection and the commitment of partners across the state, elimination is within reach.”

          About 40 other hospitals, health care organizations and companies join MD Anderson in the coalition that launched the Lonestar Plan. Those based in Houston include Houston Methodist, Rice University, UTHealth Houston, Texas Children's Hospital, Houston Health Department and others.

          The CPRIT also announced its Texans Conquer Cancer Awards and its CPRIT Champion awards during the Innovations Conference this week. Several are based in Houston, including:

          • Zhiqiang An, co-founder of CrossBridge Bio, Director of the Texas Therapeutics Institute, and Vice President of Drug Discovery at the University of Texas Health Science Center at Houston
          • Dr. Abbey Berenson, Director of the UTMB Center for Interdisciplinary Research in Women's Health Care
          • Dr. Michael Taylor, Chair of Pediatric Neuro-Oncology at Texas Children's Cancer and Hematology Center and Director of Texas Children's Pediatric Brain Tumor Research Program

          To date, the CPRIT has awarded more than $4.2 billion in grants to fight cancer in the state. Over the summer, it awarded four $2 million grants to institutions in Houston and Bryan for the creation or expansion of “core” cancer research facilities.

          Texas Medical Center Innovation recently announced that its $2 million grant would renew its Accelerator for Cancer Therapeutics for five years. Read more from TMCi about the renewal here.

          Announcing the 2026 Houston Innovation Awards finalists

          Inspirational Innovators

          InnovationMap is proud to reveal the finalists for the 2026 Houston Innovation Awards.

          The sixth annual Houston Innovation Awards program returns in an all-digital format this fall to honor the best of Houston's innovation ecosystem, including startups, entrepreneurs, mentors, and more.

          Finalists were determined by our esteemed panel of judges, comprised of past award winners and InnovationMap editorial leadership.

          The panel reviewed applications across 10 prestigious categories to determine our finalists. They will select the winner for each category, except for Startup of the Year, which will be chosen by the public via online voting launching later this month.

          We will announce the honoree of our annual Trailblazer Award in the coming weeks, then stay tuned as we unveil all of this year's winners on InnovationMap.com in mid-November.

          Get to know our finalists in more detail through editorial spotlights leading up to the winner announcement. Without further ado, here are the 2026 Houston Innovation Awards finalists:

          Minority-founded Business

          Honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation:

          • AI Made Fun
          • Deep Anchor Solutions
          • HEXAspec
          • Prana Surgical
          • Torres Orbital Mining Inc.

          Female-founded Business

          Honoring an innovative startup founded or co-founded by a woman:

          • Adair
          • ARIX Technologies
          • Bairitone Health
          • FlowCellutions
          • ParaDocs Health

          Energy Transition Business

          Honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy and beyond:

          • Capwell Services
          • FlowCellutions
          • Hertha Metals
          • Mars Materials
          • Solidec

          Health Tech Business

          Honoring an innovative startup within the health and medical technology sectors:

          • Bairitone Health
          • InformAI Inc.
          • Prana Surgical
          • Skybound MedTech

          Deep Tech Business

          Honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics and space sectors:

          • Casimir
          • Focis AI
          • Machine Saver Inc.
          • Square Robot
          • Venus Aerospace

          Startup of the Year (People's Choice)

          Honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an online voting experience:

          • Fluxworks
          • IronLattice
          • Lumino
          • Progress Report
          • Rosarium Health
          • Thread
          • TokenRoster

          Scaleup of the Year

          Honoring an innovative later-stage startup that's recently reached a significant milestone in company growth:

          • Erock
          • Hertha Metals
          • Venus Aerospace

          Incubator/Accelerator of the Year

          Honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups:

          • Activate
          • Impact Hub Houston
          • MarMo Innovation

          Mentor of the Year

          Honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs:

          • Al Danto, Rice University
          • Eric Rubenstein, New Climate Ventures
          • Jeremy Pitts, Activate
          • Joe Alapat, Liongard
          • Kyle Judah, Rice University's Liu Idea Lab for Innovation & Entrepreneurship
          • Rachel Bickham, Bickham Services Unlimited LLC

          Trailblazer Recipient

          • To be announced